What does the evidence say about Walnut Lipid Profile Randomized Trial?

The current Migaku evidence database contains 1 reusable source document for Walnut Lipid Profile Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Although several clinical trials have examined their impact on the lipid profile, results have been inconsistent, and evidence regarding their effects on apolipoproteins is limited. [Mashayekhi G (2026); evidence level 1] - The pooled analysis of 49 RCTs (57 effect sizes; 4611 participants) showed that Walnut consumption significantly reduced and TG (WMD: -6.24 mg/dL, 95% CI: [-9.49, -2.99], p p p p = 0.145), Apo-A1 (WMD: 0.0, 95% CI: [-0.01, 0.00], p = 0.573), or Apo-B (WMD: 0.1, 95% CI: [-0.02, 0.05], p = 0.462). [Mashayekhi G (2026); evidence level 1] - In conclusion, walnut supplementation improves the lipid profile by significantly lowering TC, LDL-C, and TG levels. [Mashayekhi G (2026); evidence level 1] - Walnuts ( Juglans regia L.) are rich in polyunsaturated fatty acids (PUFAs), fiber, and bioactive compounds that may positively affect lipid metabolism. [Mashayekhi G (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.